uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study

The aim of this Phase II study was to investigate the potential for response assessment and prognostication of positron emission tomography (PET) using the ligand ⁶⁸Ga-NOTA-AE105 targeting the urokinase-type plasminogen activator receptor (uPAR) in patients receiving Radium-22...

Full description

Bibliographic Details

Published in:	Diagnostics
Main Authors:	Marie Øbro Fosbøl, Jann Mortensen, Peter Meidahl Petersen, Annika Loft, Jacob Madsen, Andreas Kjaer
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Subjects:	urokinase-type plasminogen activator receptor (uPAR) prostate cancer PET Radium-223 therapy
Online Access:	https://www.mdpi.com/2075-4418/11/6/1087